N@N

Stem Cell Therapeutics Corp.: Dr. Steven C. Cramer Presents Stem Cell Therapeutics Corp.'s Final Phase IIa BETAS Safety Trial R

_{//business-finance.news-articles.net/content/200 .. corp-s-final-phase-iia-betas-safety-trial-r.html}
^{Published in Business and Finance on Thursday, February 19th 2009 at 11:30 GMT, Last Modified on 2009-02-19 11:31:35 by Market Wire}  

CALGARY, ALBERTA--(Marketwire - Feb. 19, 2009) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) is pleased to announce a presentation of the complete positive results of the Phase IIa BETAS trial conducted by Drs. Steven Cramer, Michael Hill and David Brown at the International Stroke Conference, February 19, 2009 in San Diego, CA.

The poster presentation is entitled "Safety of Beta-hCG and EPO in Acute Ischemic Stroke" and is a comprehensive evaluation of the safety and efficacy results of the completed Phase IIa BETAS trial.

Analysis of this trial by Dr. Steven C. Cramer, the Principle Investigator, highlights three key conclusions:

1. No Safety Concerns were present: NTx(TM)-265 administered to 12 patients with Acute Ischemic Stroke showed no Serious Adverse Events related to treatment.

2. ALL 12 patients enrolled in the trial and completing day 90 review improved; each recovered at least 4 points on the [ National Institute of Health Stroke Scale ] (NIHSS) and, on average, patient improved was greater than 6 points.

3. The 9 day treatment of beta-human Chorionic Gonadotropin (b-hCG) followed by Erythropoietin (EPO), started within 48 hours of stroke onset, and directly translated from a preclinical protocol, is safe. This therapy had minimal hematological effects, and was associated with significant clinical gains.

[ About Stem Cell Therapeutics Corp ].: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as [ traumatic brain injury ], [ multiple sclerosis ], [ Huntington's disease ], [ Alzheimer's disease ], and [ ALS ].

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.